This trial is active, not recruiting.

Condition superficial thrombophlebitis
Treatments dalteparin
Phase phase 4
Sponsor University Medical Centre Ljubljana
Start date September 2010
End date November 2011
Trial size 300 participants
Trial identifier NCT01245998, REVETR2010


The aim of the study is to establish whether treatment of ST with low-molecular-weight heparin in preventive or therapeutic doses prevents disease progression and thromboembolic events (deep vein thrombosis and pulmonary embolism), whether efficacy of low-molecular-weight heparin differs with regard to the dosage used (prevention, treatment), and to recognize groups of patients in which treatment with heparin is most efficient, as well as to determine factors that influence the efficacy of ST treatment with heparin.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
(Active Comparator)
dalteparin Fragmin
dalteparin 5000 I.U./24 h s.c. for 6 weeks
(Active Comparator)
dalteparin Fragmin
dalteparin 15000 I.U./24 h s.c. for 6 weeks

Primary Outcomes

To assess the efficacy and safety of low-molecular-weight heparin - dalteparin in patients with ST
time frame: 3 months
Combined end-point: occurrence of symptomatic or asymptomatic deep vein thrombosis, symptomatic pulmonary embolism or ultrasonographic blood clot progression or relapse of ST
time frame: 3 months
Clinically relevant bleeding occurring
time frame: during treatment

Secondary Outcomes

To investigate the safety of ST treatment with preventive doses of dalteparin compared with therapeutic doses, death, bleeding, HIT
time frame: 3 months
To ascertain whether the extent or progression of ST is related to systemic inflammatory parameters
time frame: 12 months
To study a possible correlation between effectiveness of treatment of ST with preventive and therapeutic doses of dalteparin and severity of systemic inflammatory parameters.
time frame: 12 months
To determine whether the extension of anticoagulant treatment with the study drug for additional six weeks is more effective and safer
time frame: 3 months

Eligibility Criteria

Male or female participants from 18 years up to 85 years old.

Inclusion Criteria: - written informed consent to participate in the study - symptomatic thrombophlebitis of the great saphenous vein measuring at least 10 cm or the small saphenous vein measuring at least 10 cm or a collateral of the great saphenous vein measuring at least 10 cm (within 7 days from the onset of the disease) - age 18 to 85 years - body weight 65 to 85 kg Exclusion Criteria: - inability to objectively confirm the diagnosis - excessive or insufficient body weight (more than 85 kg or less than 60 kg) - history of previous thromboembolic complications (including previous thrombophlebitis, vein thrombosis and pulmonary embolism) - contraindications for anticoagulant treatment - active bleeding or high risk for bleeding contraindicating treatment with (LMWH) - diseases requiring anticoagulant treatment - proximal or distal deep vein thrombosis or pulmonary embolism (either symptomatic or incidentally found asymptomatic) - thrombophlebitis of the great saphenous vein at a distance of less than 5 cm from the saphenofemoral junction or thrombophlebitis of small saphenous vein at a distance of less than 3 cm from the saphenopopliteal junction - thrombophlebitis that might arise as a consequence of a previous intravenous access (infusion thrombophlebitis), sclerotherapy or surgical treatment of chronic vein insufficiency - pregnancy, known malignant disease or chemotherapy - immobility - advanced stage of kidney failure (GF < 30 mL/min/1.72 m2) - significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT) >\= 2 times the upper limit of normal (ULN), or total bilirubin (TBL) x 1.5 times the ULN

Additional Information

Official title Prospective, Randomized, Double-blinded Trial of the Efficacy and Safety of Different Doses and Duration of Low Molecular Weight Heparin (Dalteparin) in Superficial Vein Thrombosis
Principal investigator Pavel Poredos, M.D., Ph.D.
Description Until recently thrombophlebitis was regarded as a benign and self-limiting disease. Recent studies have shown that various complications, especially vein thrombosis and pulmonary thromboembolism, often accompany ST. An observational study (Prospective Observational Superficial Thrombophlebitis - POST) showed that three months after onset of the disease thromboembolic events occurred in 10% of patients: pulmonary embolism in 0.4%, disease progression in 3.1% and disease recurrence in 1.9% of patients. Therefore, ST is now frequently regarded as a part of the thromboembolic syndrome. On the basis of the evidence referred to above anticoagulants, especially heparin, are used more and more often for treatment of ST instead of anti-inflammatory drugs and non-steroidal antirheumatics. Several studies performed so far have examined efficacy of standard and low-molecular-weight heparin in various doses, but no final conclusion on the efficacy of treatment of ST with heparin has been established yet. A study by Marchiori and colleagues showed that 8-12-day treatment of ST with preventive and therapeutic doses of low-molecular-weight heparin significantly reduces progression and relapse of the disease, but not its thromboembolic complications. Another study demonstrated that low-molecular-weight heparin in combination with elastic compression was not significantly more effective than compression alone. Comparison of preventive and therapeutic doses of low-molecular-weight heparin given to patients over the period of one month after disease onset showed no differences in the efficacy in prevention of disease progression and thromboembolic complications. The standard (unfractionated) heparin was also shown to be effective in preventing disease progression, however, but not in preventing thromboembolic complications. It is also not clear how long the treatment with heparin should last. So far only one study compared the efficacy of treatment with various doses of low-molecular-weight heparin from one month to three months' duration; it demonstrated that 1-month treatment with lower doses of heparin was as effective as 3-month treatment with therapeutic doses of heparin. A recent study (CALISTO) compared efficacy of preventive doses of fondaparinux (2.5 mg) with placebo in more than 3,000 patients with ST and concluded that anticoagulant treatment of ST probably does not significantly influence prevention of thromboembolic complications (Abstract presented at the 5th ASA Annual Meeting of the American Society of Hematology). Results of recent studies therefore show that heparin (standard or low-molecular-weight heparin) in various doses prevents ST progression, but no final agreement has emerged as to whether they prevent occurrence of thromboembolic complications as well. Interpretation of the results is difficult because of the heterogeneity of the patients included in certain studies and especially because of unavailability of subgroup analyses, which would help to establish whether treatment with heparin is more effective in certain groups of patients with ST than in those with presenting forms of the disease. Latest (2008) guidelines for prevention of venous thromboembolic events adopted by the American College of Chest Physicians (ACCP) recommend treatment with at least preventive or median doses of low-molecular-weight heparin or standard heparin for the duration of not less than 4 weeks. This recommendation is based on a very low evidence level (level 2B). In this study the investigators will therefore try to ascertain whether the extensiveness of thrombophlebitis and the distance of the end of blood clot from saphenofemoral and saphenopopliteal junction influence the efficacy of ST treatment with heparin. The investigators shall also monitor the expression of systemic inflammatory parameters that might be related to the efficacy of the treatment and progression of the disease.
Trial information was received from ClinicalTrials.gov and was last updated in November 2010.
Information provided to ClinicalTrials.gov by University Medical Centre Ljubljana.